New combo therapy aims to calm gut side effects from cancer drugs

NCT ID NCT06841705

Recruiting now Disease control Sponsor: Shilpa Grover, MD, MPH Source: ClinicalTrials.gov ↗

First seen Nov 06, 2025 · Last updated May 17, 2026 · Updated 22 times

Summary

This study tests whether a drug called vedolizumab, given with a short course of steroids, works better than standard steroids alone for treating colitis (inflammation of the colon) caused by immune checkpoint inhibitors used in cancer treatment. About 80 adults who have this type of colitis will receive either vedolizumab plus short steroids or standard steroids. The main goal is to see if more people achieve remission without needing long-term steroids or other rescue treatments by 8 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS